Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 496

1.

Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?

You JH, Kei HW, Lau WC, Wong KY, Marasinghe T, Lee N, Ip M.

J Hosp Infect. 2008 Feb;68(2):181-3. doi: 10.1016/j.jhin.2007.11.014. Epub 2008 Jan 14. No abstract available.

PMID:
18194826
2.

Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.

Peña C, Gudiol C, Calatayud L, Tubau F, Domínguez MA, Pujol M, Ariza J, Gudiol F.

J Hosp Infect. 2008 Feb;68(2):116-22. doi: 10.1016/j.jhin.2007.11.012. Epub 2008 Jan 15.

PMID:
18226420
3.

Addressing the challenge of extended-spectrum beta-lactamases.

Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P.

Curr Opin Investig Drugs. 2009 Feb;10(2):172-80. Review.

PMID:
19197795
4.

Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Krueger WA, Kempf VA, Peiffer M, Nagele U, Unertl KE, Schroeder TH.

J Clin Microbiol. 2008 Feb;46(2):817-20. Epub 2007 Dec 12.

5.

[Attention-getting cross infections: Extended-spectrum beta-lactamase-producing bacterial infections].

Yoshida A.

Nihon Naika Gakkai Zasshi. 2007 Nov 10;96(11):2470-5. Review. Japanese. No abstract available.

PMID:
18069300
6.

Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.

Lagacé-Wiens PR, Nichol KA, Nicolle LE, DeCorby M, McCracken M, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2006 Jun;57(6):1262-3. Epub 2006 Mar 24. No abstract available.

PMID:
16565157
7.

Ciprofloxacin and co-trimoxazole resistance and extended spectrum beta-lactamase production in Escherichia coli strains isolated from urinary tract infections.

Ozden M, Kalkan A, Demirdag K, Kilic SS, Ozdarendeli A.

Int J Antimicrob Agents. 2003 May;21(5):492-3. No abstract available.

PMID:
12727086
8.

Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Metan G, Zarakolu P, Cakir B, Hascelik G, Uzun O.

Int J Antimicrob Agents. 2005 Sep;26(3):254-7.

PMID:
16122910
9.

Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.

Lepeule R, Ruppé E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B.

Antimicrob Agents Chemother. 2012 Mar;56(3):1376-81. doi: 10.1128/AAC.06233-11. Epub 2012 Jan 3.

10.

Community-acquired extended-spectrum beta-lactamase producers, United States.

Doi Y, Adams J, O'Keefe A, Quereshi Z, Ewan L, Paterson DL.

Emerg Infect Dis. 2007 Jul;13(7):1121-3. doi: 10.3201/eid1307.070094. No abstract available.

11.

Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen.

Lee CH, Su LH, Lin WC, Tang YF, Liu JW.

Int J Infect Dis. 2010 Sep;14 Suppl 3:e183-6. doi: 10.1016/j.ijid.2009.06.023. Epub 2009 Oct 1.

12.

Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia.

Lye DC, Wijaya L, Chan J, Teng CP, Leo YS.

Ann Acad Med Singapore. 2008 Oct;37(10):831-4.

13.

Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Ena J, Arjona F, Martínez-Peinado C, López-Perezagua Mdel M, Amador C.

Urology. 2006 Dec;68(6):1169-74.

PMID:
17169640
14.

Emergence of carbapenem-resistant Escherichia coli producing CMY-2-type AmpC beta-lactamase in Brazil.

Pavez M, Neves P, Dropa M, Matté MH, Grinbaum RS, Elmor de Araújo MR, Mamizuka EM, Lincopan N.

J Med Microbiol. 2008 Dec;57(Pt 12):1590-2. doi: 10.1099/jmm.0.2008/002774-0. No abstract available.

PMID:
19018036
15.

Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4.

Peirano G, Pitout JD.

Int J Antimicrob Agents. 2010 Apr;35(4):316-21. doi: 10.1016/j.ijantimicag.2009.11.003. Epub 2010 Jan 13. Review.

PMID:
20060273
16.

Prevalence of extended spectrum beta lactamase and AmpC beta lactamase producers among Escherichia coli isolates in a tertiary care hospital in Jaipur.

Sinha P, Sharma R, Rishi S, Sharma R, Sood S, Pathak D.

Indian J Pathol Microbiol. 2008 Jul-Sep;51(3):367-9.

17.

Analysis of the beta-lactam resistance phenotypes of Escherichia coli. An 8-year survey conducted in Greece.

Neonakis IK, Baritaki S, Georgiladakis A, Spandidos DA.

Roum Arch Microbiol Immunol. 2008 Jan-Jun;67(1-2):10-3.

PMID:
19284160
18.

Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes.

Ho PL, Wong RC, Yip KS, Loke SL, Leung MS, Mak GC, Chow FK, Tsang KW, Que TL; COMBAT study group.

Diagn Microbiol Infect Dis. 2007 Dec;59(4):439-45. Epub 2007 Sep 20.

PMID:
17888610
19.

[Microbiol landscape and production of beta-lactamases with extended spectrum activity in patients with urinary tract infection].

Zhevlakova IuA, Zakharova GV, Khokhlova OI, Ust'iantseva IM.

Klin Med (Mosk). 2009;87(3):56-9. Russian.

PMID:
19469259
20.

First identification of an Escherichia coli clinical isolate producing both metallo-beta-lactamase VIM-2 and extended-spectrum beta-lactamase IBC-1.

Galani I, Souli M, Chryssouli Z, Katsala D, Giamarellou H.

Clin Microbiol Infect. 2004 Aug;10(8):757-60.

Supplemental Content

Support Center